OncoMatch

OncoMatch/Clinical Trials/NCT05686798

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Is NCT05686798 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) for malignant glioma of brain.

Phase 1RecruitingHenry Ford Health SystemNCT05686798Data as of May 2026

Treatment: Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Disease stage

Grade: high-grade

radiologic evidence of intracranial recurrence or progression of a previously diagnosed high-grade astrocytoma

Prior therapy

Must have received: radiation therapy

An interval of at least 3 months must have elapsed since the completion of the most recent course of radiation

Cannot have received: gene or virus therapy

No prior treatment of the tumor with gene or virus therapy

Cannot have received: immunotherapy

No prior treatment of the tumor with...immunotherapy

Cannot have received: brachytherapy

No prior treatment of the tumor with...brachytherapy

Cannot have received: polymer implant containing chemotherapeutic agents (Gliadel Wafer)

No prior treatment of the tumor with...implants of polymers containing chemotherapeutic agents (e.g. Gliadel Wafer)

Lab requirements

Blood counts

platelet count ≥ 100,000/μl; absolute neutrophil count ≥ 1,000/μl; hemoglobin > 10.0 g/dl

Kidney function

creatinine clearance ≥ 50 ml/min/m2

Liver function

bilirubin < 1.5 mg/dl; sgot and sgpt < 2.5 times upper limit of normal (uln)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Henry Ford Health System · Detroit, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify